July 25, 2024 – Page 10 – Goldea Capital

Proteomics Market Projected to Grow at 16.55% CAGR by 2031 | SkyQuest Technology

Written by Customer Service on July 25, 2024. Posted in Mergers And Acquisitions.

Westford USA, July 25, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that Proteomics Market will attain a value of USD 100.17 billion by 2031, with a CAGR of 16.55% during the forecast period (2024-2031). CVD is one of the leading causes of death worldwide. According to the World Health Organization, targeted diseases kill 41 million people each year. Thus, with the prevalence of life-threatening diseases, the demand for generic medicines increases, creating a positive impact on the industry. The National Institutes of Health (NIH) provided the $37 billion for medical research. These funds were to support life science research that sought to understand key mechanisms of disease progression, such as identifying biomarkers of disease or identifying genes/proteins causing disease. The market is also expected to carry the flow leading...

Independent Bank Corporation Reports 2024 Second Quarter Results

Written by Customer Service on July 25, 2024. Posted in Earnings Releases And Operating Results.

Second Quarter Highlights Highlights for the second quarter of 2024 include: Increases in net income and diluted earnings per share of 25.3% and 25.7%, respectively, over second quarter of 2023; An increase in tangible book value per share of $2.71 (16.5%) over the second quarter of 2023; Net growth in core deposits of $53.3 million (or 4.8% annualized) from March 31, 2024; Net growth in loans of $11.9 million (or 1.2% annualized) from March 31, 2024; and The payment of a 24 cent per share dividend on common stock on May 13, 2024. GRAND RAPIDS, Mich., July 25, 2024 (GLOBE NEWSWIRE) — Independent Bank Corporation (NASDAQ: IBCP) reported second quarter 2024 net income of $18.5 million, or $0.88 per diluted share, versus net income of $14.8 million, or $0.70 per diluted share, in the prior-year period. William B. (“Brad”) Kessel,...

Fentura Financial, Inc. Announces Second Quarter 2024 Earnings (Unaudited)

Written by Customer Service on July 25, 2024. Posted in Earnings Releases And Operating Results.

Dollars in thousands except per share amounts. Certain items in the prior period financial statements have been reclassified to conform with the June 30, 2024 presentation. FENTON, Mich., July 25, 2024 (GLOBE NEWSWIRE) — Fentura Financial, Inc. (OTCQX: FETM) announces quarterly net income results of $1,980 and $4,770 for the three and six months ended June 30, 2024, respectively. Ronald L. Justice, President and CEO, stated, “Our second quarter results are in line with our expectations as we pursue near-term strategies aimed at navigating a difficult banking environment. We continue to focus on strengthening our balance sheet by controlling loan growth, managing our cost of funds, and maintaining robust asset quality. During the first half, gross loans remained stable as a result of higher home equity loans, consistent commercial...

VitalHub Announces Q2 2024 Conference Call Date

Written by Customer Service on July 25, 2024. Posted in Public Companies.

TORONTO, July 25, 2024 (GLOBE NEWSWIRE) — VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI) (OTCQX:VHIBF) is pleased to announce that it will release its financial results for its second quarter 2024 ended June 30th, 2024, after market close on August 8th, 2024. The Company will subsequently hold a conference call via Zoom on August 9th, 2024, at 9:00am EST hosted by CEO Dan Matlow and CFO Brian Goffenberg with a Q&A session to follow. To register for the conference call please visit: https://us02web.zoom.us/webinar/register/WN_-Es4D85lTaCMdHGDz9A15w ABOUT VITALHUB: Software for Health and Human Services providers designed to simplify the user experience and optimize outcomes. VitalHub is a leading software company dedicated to empowering Health and Human Services providers. Our clients include hospitals, regional health...

Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research

Written by Customer Service on July 25, 2024. Posted in Public Companies.

Study aims to build a comprehensive, open-source database of heritable genetics and patient-reported data in lung cancer SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) — 23andMe Holding Co. (Nasdaq: ME), a leading genetic health and biopharmaceutical company, in collaboration with 20 lung cancer advocacy organizations, today announced a new study to help advance research in lung cancer. The focus of the Lung Cancer Genetics Study is to better understand the genetics of people with lung cancer in order to improve detection, risk reduction, and care. While recent developments in tumor genetic testing and targeted therapies have provided hope and years of survival to many lung cancer patients, lung cancer remains the number one cause of cancer deaths in both men and women in the United States. Yet, much remains unknown about the...

CoreCard to Participate in August 2024 Investor Conferences

Written by Customer Service on July 25, 2024. Posted in Public Companies.

NORCROSS, Ga., July 25, 2024 (GLOBE NEWSWIRE) — CoreCard Corporation [NYSE: CCRD], the leading provider of innovative credit technology solutions and processing services to the financial technology and services market, today announced that Leland Strange, President & CEO, and Matt White, CFO, will be participating in the following investor conferences: KeyBanc Technology Leadership Forum on August 6, 2024 in Vail, CO. Oppenheimer 27th Annual Technology, Internet & Communications Conference on August 14, 2024 (virtual). Seaport Financials and FinTech Conference on August 15, 2024 (virtual). If you would like to schedule time to meet with the Company at the conferences, please reach out to the hosting bank. About CoreCard CoreCard Corporation (NYSE: CCRD) provides the gold standard card issuing platform built for the...

Kelly Announces Second-Quarter 2024 Conference Call

Written by Customer Service on July 25, 2024. Posted in Public Companies.

TROY, Mich., July 25, 2024 (GLOBE NEWSWIRE) — Kelly, a leading global specialty talent solutions provider, will release its second-quarter earnings before the market opens on Thursday, August 8, 2024. In conjunction with its second-quarter earnings release, Kelly will publish a financial presentation on the Investor Relations page of its public website and will host a conference call at 9 a.m. ET. The call may be accessed in one of the following ways: Via the internet:kellyservices.com Via the telephone:(877) 692-8955 (toll free) or (234) 720-6979 (caller paid)Enter access code 5728672After the prompt, please enter “#” A recording of the conference call will be available after 1:30 p.m. ET on August 8, 2024, at (866) 207-1041 (toll-free) and (402) 970-0847 (caller-paid). The access code is 2784290#. The recording will also be available...

SIGA to Host Business Update Call on August 1 Following Release of Second-Quarter 2024 Financial Results

Written by Customer Service on July 25, 2024. Posted in Public Companies.

NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, August 1, 2024. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company’s website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. A replay of the call will be available for two weeks by dialing 1-844-512-2921...

Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology

Written by Customer Service on July 25, 2024. Posted in Public Companies.

Weekly subcutaneous doses of pemvidutide resulted in up to 68.5% relative reduction in liver fat content (LFC), with up to 55.6% of subjects achieving LFC normalization after 12 weeks of treatment LFC changes were accompanied by significant improvements in body weight and non-invasive markers of liver inflammation Pemvidutide is currently being evaluated in the Phase 2b IMPACT trial in subjects with metabolic dysfunction-associated steatohepatitis (MASH), with data readout expected in Q1 2025 GAITHERSBURG, Md., July 25, 2024 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the data from its 12-week clinical trial of pemvidutide, an investigational GLP-1/glucagon dual receptor agonist, in metabolic dysfunction-associated steatotic liver disease (MASLD) has been published...

OptimizeRx Sets Second Quarter 2024 Conference Call for August 8, 2024 at 4:30 p.m. ET

Written by Customer Service on July 25, 2024. Posted in Public Companies.

WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Thursday, August 8, 2024, at 4:30 p.m. Eastern Time to discuss its results for the second quarter period ended June 30, 2024. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date: Thursday, August 8, 2024 Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) Toll Free: 1-800-343-4849 International: 1-203-518-9848 Conference ID: OPRXQ2 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1679004&tp_key=4b22d66114 Please...

Day: July 25, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice